文献速递创伤与烧伤心脑血管急症

超治疗范围华法林与老年钝性头部创伤患者颅内出血风险

Supratherapeutic warfarin and risk of intracranial hemorrhage in geriatric patients with blunt head trauma.
PubMed 文献 · Am J Emerg Med · 2025-06-14
一句话结论老年急诊头部创伤患者伤前服用华法林时,INR>3.0似乎不是急性颅内出血的危险因素。

本研究为一项前瞻性研究的二次分析,纳入两家急诊科一年内因平地跌倒导致头部创伤的老年患者,比较伤前服用华法林与未服用抗凝或抗血小板药物患者的CT诊断颅内出血率。共2686例符合纳入标准,其中未服用抗凝或抗血小板药物组2423例,华法林组263例。华法林组平均年龄85.3岁,高于未服用组的80.2岁(p<0.5);华法林组女性占40%,未服用组女性占60.2%。当INR>3.0时,华法林组与未服用组的颅内出血率无显著差异。结论认为,老年急诊患者伤前服用华法林时,INR升高似乎不是急性颅内出血的危险因素。

要点

  • 老年急诊头部创伤患者伤前服用华法林时,INR>3.0与未服用抗凝或抗血小板药物者相比,颅内出血率无显著差异。
  • 研究纳入平地跌倒的老年头部创伤患者,排除服用非华法林抗凝药或未服用华法林的抗血小板药患者。
  • 华法林组平均年龄85.3岁,高于未服用组的80.2岁(p<0.5);华法林组女性占40%,未服用组女性占60.2%。
  • 共2686例符合纳入标准,其中未服用抗凝或抗血小板药物组2423例,华法林组263例。
  • 作者结论认为,老年急诊患者伤前服用华法林时,INR升高似乎不是急性颅内出血的危险因素。

适用人群与场景

  • 老年急诊头部创伤患者,纳入标准为平地跌倒导致的头部创伤。
  • 排除服用非华法林抗凝药的患者,以及未服用华法林的抗血小板药患者。

诊断标准与关键阈值

  • 以INR>3.0作为超治疗范围的界值。

研究设计与关键结果

  • 研究类型为前瞻性研究的二次分析,纳入两家急诊科一年内的老年头部创伤患者,共2686例符合纳入标准。
  • 未服用抗凝或抗血小板药物组2423例,华法林组263例。
  • 华法林组平均年龄85.3岁,未服用组80.2岁(p<0.5);华法林组女性占40%,未服用组女性占60.2%。
  • 在INR>3.0时,华法林组与未服用抗凝或抗血小板药物组的颅内出血率无显著差异。

证据类型、等级与局限

  • 证据类型为前瞻性研究的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,老年急诊患者伤前服用华法林时,INR升高似乎不是急性颅内出血的危险因素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: The aim of our study is to assess whether a supratherapeutic international normalized ratio (INR) is associated with an increased risk of intracranial hemorrhage (ICH) in geriatric ED patients prescribed preinjury warfarin that suffer head trauma.

METHODS: This was a secondary analysis of a prospective study of geriatric head trauma patients presenting to two EDs over a one-year period. Geriatric ED patients presenting with a head injury were enrolled. Inclusion criteria were patients who sustained a ground level fall. Exclusion criteria were patients taking non-warfarin anticoagulants or patients taking antiplatelet agents not on warfarin. The primary study outcome was an ICH diagnosed on CT scan. Data included demographics, anticoagulant use, antiplatelet use, physical examination findings and head CT results. The main outcome measure was significant head injury based on therapeutic versus supratherapeutic INR.

RESULTS: Of 5776 patients identified, 2686 met inclusion criteria. There were 2423 in the No ACAP group and 263 in the warfarin. The patients in the no anticoagulants or antiplatelet group (No ACAP) were younger than the Warfarin: mean age 80.2 versus 85.3 years (p < 0.5). The groups also differed by gender with 60.2 % females in the No ACAP and 40 % females in the Warfarin. When comparing ICH rates in patients on warfarin versus NO ACAP with an INR > 3.0, there were no significant differences.

CONCLUSION: In older ED patients prescribed preinjury warfarin, elevated INR levels do not appear to be a risk factor for acute ICH.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Caplan C, Engstrom G, Wells M, et al. Supratherapeutic warfarin and risk of intracranial hemorrhage in geriatric patients with blunt head trauma. Am J Emerg Med. 2025. PMID: 40540788. doi:10.1016/j.ajem.2025.06.020

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。